Nortriptyline
- 2 independent labs in 2 countries
- Funders: National Natural Science Foundation of China and 2 more
- Animals2
Outcomes
3Gastric cancer
downin humans1
1 study
Gastric cancer
downin humans1
Nortriptyline decreases gastric cancer in humans.
“Nor administration attenuates lysosomal exocytosis-mediated senescence-associated secretory phenotype (SASP) and reduces aggressive phenotypes in gastric cancer models”
Animalsin gastric cancer models
Advanced science (Weinheim, Baden-Wurttemberg, Germany)25 Sep 2025
Senescence-associated secretory phenotype (SASP)
downin humans1
1 study
Senescence-associated secretory phenotype (SASP)
downin humans1
Nortriptyline inhibits senescence-associated secretory phenotype (SASP) in humans.
“Nor administration attenuates lysosomal exocytosis-mediated senescence-associated secretory phenotype (SASP)”
Animalsin gastric cancer models
Advanced science (Weinheim, Baden-Wurttemberg, Germany)25 Sep 2025
Lifespan
upin mice1
1 study
Lifespan
upin mice1
Nortriptyline extends lifespan in mice.
“nortriptyline significantly delayed disease onset and extended the lifespan of ALS mice”
Animalsin ALS mice
Nortriptyline delays disease onset in models of chronic neurodegeneration
The European journal of neuroscience1 Aug 2007
Latest
The European Journal of Neuroscience
Nortriptyline delays disease onset in models of chronic neurodegeneration
Experiments in miceNeurodegenerative disease